ETX 258
Alternative Names: ETX-258Latest Information Update: 04 Nov 2024
Price :
$50 *
At a glance
- Originator e-Therapeutics
- Class Amides; Amino sugars; Cardiovascular therapies; Drug conjugates; Heart failure therapies; Small interfering RNA
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Heart failure
Most Recent Events
- 31 Oct 2024 Preclinical trials in Heart failure in United Kingdom (SC) prior to October 2024
- 22 Oct 2024 Early research in Heart failure in United Kingdom (SC) before October 2024 (e-Therapeutics pipeline, October 2024)
- 27 Oct 2023 ETX 258 is available for licensing as of 27 Oct 2023. https://www.etherapeutics.co.uk/our-science/therapeutic-pipeline/ (e-Therapeutics website, October 2023)